News
ALRN
2.580
-6.52%
-0.180
Weekly Report: what happened at ALRN last week (1111-1115)?
Weekly Report · 4d ago
Friday Sector Laggards: Biotechnology, Drugs
NASDAQ · 11/15 17:15
Aileron Therapeutics GAAP EPS of -$0.27 misses by $0.02
Seeking Alpha · 11/15 11:39
Based on the provided financial report, the title of the article is: "Aileron Therapeutics, Inc. Reports Financial Results for the Quarter Ended September 30, 2024
Press release · 11/14 23:29
AILERON THERAPEUTICS, INC. Q3 EPS USD -0.27
Reuters · 11/14 21:15
*Aileron Therapeutics 3Q Loss $5.85M >ALRN
Dow Jones · 11/14 21:15
Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis
Benzinga · 11/13 18:04
Aileron Therapeutics Reports Positive Phase 1b Data Of LTI-03 In Idiopathic Pulmonary Fibrosis
NASDAQ · 11/13 12:36
Aileron reports results from Cohort 2 of its Phase 1b clinical trial of LTI-03
TipRanks · 11/13 12:11
AILERON THERAPEUTICS INC - HIGH-DOSE LTI-03 REDUCES EXPRESSION OF PROFIBROTIC PROTEINS
Reuters · 11/13 12:00
Weekly Report: what happened at ALRN last week (1104-1108)?
Weekly Report · 11/11 12:12
Weekly Report: what happened at ALRN last week (1028-1101)?
Weekly Report · 11/04 12:07
Aileron Therapeutics’ ALRN-6924 to be acquired by Advancium Health Network
TipRanks · 10/31 11:41
*Advancium Paid Aileron Non-Refundable Fee for Exclusive Option to Acquire ALRN-6924 and Related Assets >ALRN
Dow Jones · 10/31 11:40
Aileron Therapeutics And Advancium Health Network Announced An Exclusive Option Agreement For The Acquisition Of ALRN-6924, Developed By Aileron Prior To Its 2023 Merger With Lung Therapeutics
Benzinga · 10/31 11:38
*Advancium Will Evaluate ALRN-6924 as a Potential Therapy for Retinoblastoma
Dow Jones · 10/31 11:32
*Aileron Therapeutics: Agreement Marks First of Its Kind for Advancium, a Public Charity Launched by Deerfield
Dow Jones · 10/31 11:31
AILERON THERAPEUTICS AND ADVANCIUM HEALTH NETWORK ANNOUNCE AN EXCLUSIVE OPTION AGREEMENT FOR THE ACQUISITION OF ALRN-6924 FOR RETINOBLASTOMA
Reuters · 10/31 11:30
More
Webull provides a variety of real-time ALRN stock news. You can receive the latest news about Aileron Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ALRN
Aileron Therapeutics, Inc. is a biopharmaceutical company. The Company is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate, LTI-01, is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue, allowing for drainage of the pleural effusion. It has completed Phase Ib and Phase IIa clinical trials for the treatment of loculated pleural effusions.